Keyphrases
Drug Discovery
92%
Human African Trypanosomiasis
85%
Trypanosoma Brucei
82%
Visceral Leishmaniasis
79%
Chagas Disease
69%
Drug Target
62%
Trypanosoma Cruzi (T. cruzi)
61%
Mouse Model
50%
Mycobacterium Tuberculosis (M. tb)
49%
N-Myristoyltransferase Inhibitors
46%
Trypanocidal Activity
43%
N-myristoyltransferase
41%
Plasmodium Falciparum
38%
T. Brucei
38%
Antitrypanosomal Activity
33%
Central Nervous System
33%
Nifurtimox
31%
In Vivo Efficacy
30%
Phenotypic Screening
29%
Mode of Action
28%
Protozoan Parasites
28%
Anti-trypanosomatid Drugs
27%
Medicinal Chemistry
26%
Leishmania Donovani
26%
Structure-activity Relationship
26%
Malaria
25%
New Drugs
25%
Preclinical Candidate
24%
Causative Agents
24%
Antimalarial Activity
24%
Mechanism of Action
22%
Brain Penetrant
22%
Pharmacokinetic Properties
21%
Metabolic Stability
20%
Anticonvulsant
20%
Methyl
20%
Dundee
20%
Antimalarial Drugs
20%
Biological Evaluation
20%
LysR Family
20%
Wellcome
20%
Small Molecules
20%
Leishmania
19%
Current Treatment
19%
Novel Inhibitors
19%
Fexinidazole
19%
Benznidazole
19%
Pharmacokinetics
18%
Drug Development
18%
Trypanosome
18%
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
100%
African Trypanosomiasis
86%
Visceral Leishmaniasis
85%
Trypanosoma Brucei
79%
Chagas Disease
77%
Diseases
75%
Pharmacokinetics
70%
Mouse Model
57%
Antimalarial Agent
55%
Trypanosoma Cruzi
52%
Infection
44%
Structure Activity Relationship
43%
Mycobacterium Tuberculosis
37%
Carboxamide
36%
Plasmodium falciparum
36%
Protozoon
35%
Pharmaceutical Chemistry
29%
Drug Development
27%
Antimalarial Activity
26%
Prodrug
25%
Leishmania
25%
Nifurtimox
25%
Receptor
24%
Trypanosomatidae
23%
Blood-Brain Barrier
22%
Fexinidazole
21%
Trypanosoma
21%
Leishmania donovani
21%
Cytotoxicity
20%
Cyclin Dependent Kinase
20%
Lysine Transfer RNA Ligase
20%
Side Effect
19%
Antitrypanosomal
19%
Sulfonamide
19%
Oxidoreductase
18%
Anticonvulsive Agent
18%
Benznidazole
18%
Lipophilicity
17%
High-Throughput Screening
17%
Hexachlorophene
16%
Proteasome
16%
Pyrimidine Derivative
16%
Protein Kinases
16%
Therapeutic Window
16%
EC50
16%
Phosphotransferase
15%
Lead Compound
15%
Kinetoplastida
14%
Pyrimidine
14%
Clinical Trial
14%